Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2001;38:588-591

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weber, K. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weber, K. T.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Heart Diseases
*High Blood Pressure

(Hypertension. 2001;38:588.)
© 2001 American Heart Association, Inc.


Cardiovascular Biology

Cardioreparation in Hypertensive Heart Disease

Karl T. Weber

Division of Cardiovascular Diseases, Department of Medicine, University of Tennessee Health Science Center, Memphis.

Correspondence to Karl T. Weber, MD, Division of Cardiovascular Diseases, University of Tennessee Health Science Center, Room 353 Dobbs Research Institute, 951 Court Ave, Memphis, TN 38163. E-mail KTWeber{at}utmem.edu

Abstract

Abstract— The normal myocardium is composed of a variety of cells. Cardiac myocytes, tethered within an extracellular matrix of fibrillar collagen, represent one third of all cells; noncardiomyocytes account for the remaining two thirds. Ventricular hypertrophy involves myocyte growth. Hypertensive heart disease (HHD) includes myocyte and nonmyocyte growth that leads to an adverse structural remodeling of the intramural coronary vasculature and matrix. In HHD, it is not the quantity of myocardium but rather its quality that accounts for increased risk of adverse cardiovascular events. Structural homogeneity of cardiac tissue is governed by a balanced equilibrium existing between stimulator and inhibitor signals that regulate cell growth, apoptosis, phenotype, and matrix turnover. Stimulators (eg, angiotensin II, aldosterone, and endothelins) are normally counterbalanced by inhibitors (eg, bradykinin, NO, and prostaglandins) in a paradigm of reciprocal regulation. To reduce the risk of heart failure and sudden cardiac death that accompanies HHD, its adverse structural remodeling must be targeted for pharmacologic intervention. Cardioprotective agents counteract the imbalance between stimulators and inhibitors. They include ACE and endopeptidase inhibitors and respective receptor antagonists. Cardioreparative agents reverse the growth-promoting state and regress existing abnormalities in coronary vascular and matrix structure. ACE inhibition has achieved this outcome with favorable impact on vasomotor reactivity and tissue stiffness. Today’s management of hypertension should not simply focus on a reduction in blood pressure, it must also target the adverse structural remodeling that begets HHD.


Key Words: hypertrophy • fibrosis • myocardium • homeostasis




This article has been cited by other articles:


Home page
HypertensionHome page
H. Masuyama, T. Tsuruda, J. Kato, T. Imamura, Y. Asada, J.-P. Stasch, K. Kitamura, and T. Eto
Soluble Guanylate Cyclase Stimulation on Cardiovascular Remodeling in Angiotensin II-Induced Hypertensive Rats
Hypertension, November 1, 2006; 48(5): 972 - 978.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. R. van Kimmenade, J. L. Januzzi Jr, P. T. Ellinor, U. C. Sharma, J. A. Bakker, A. F. Low, A. Martinez, H. J. Crijns, C. A. MacRae, P. P. Menheere, et al.
Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure
J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1217 - 1224.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
P. M. Heerdt, S. Klotz, and D. Burkhoff
Cardiomyopathic Etiology and SERCA2a Reverse Remodeling During Mechanical Support of the Failing Human Heart
Anesth. Analg., January 1, 2006; 102(1): 32 - 37.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
O. H. Cingolani, X.-P. Yang, Y.-H. Liu, M. Villanueva, N.-E. Rhaleb, and O. A. Carretero
Reduction of Cardiac Fibrosis Decreases Systolic Performance Without Affecting Diastolic Function in Hypertensive Rats
Hypertension, May 1, 2004; 43(5): 1067 - 1073.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
P. Finckenberg, K. Inkinen, J. Ahonen, S. Merasto, M. Louhelainen, H. Vapaatalo, D. Muller, D. Ganten, F. Luft, and E. Mervaala
Angiotensin II Induces Connective Tissue Growth Factor Gene Expression via Calcineurin-Dependent Pathways
Am. J. Pathol., July 1, 2003; 163(1): 355 - 366.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. R. Boheler, M. Volkova, C. Morrell, R. Garg, Y. Zhu, K. Margulies, A.-M. Seymour, and E. G. Lakatta
Sex- and age-dependent human transcriptome variability: Implications for chronic heart failure
PNAS, March 4, 2003; 100(5): 2754 - 2759.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
A Gonzalez, B Lopez, and J Diezl
Myocardial fibrosis in arterial hypertension
Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D18 - D22.
[Abstract] [PDF]